is tirzepatide insulin against obesity and insulin-resistance: pathophysiological aspects and clinical evidence Tirzepatide (Mounjaro): A Dual-Action Breakthrough

Ishibashi, M

In the Phase 2 clinical trial published in the New England Journal of Medicine (2023), participants receiving retatrutide achieved mean weight reductions of up to approximately 24% over 48 weeks

Open communication with your healthcare provider about cancer concerns is essential when considering weight loss injections

The renal outcome was a composite of nephropathy, defined as the new onset of macroalbuminuria or a doubling of the serum creatinine level and an eGFR of 45 mL/min per 1.73 m2, the need for continuous renal replacement therapy, or death from renal disease

In addition to its primary functions, tirzepatide also influences appetite regulation by acting on the brain's hunger centers

If your GI symptoms or other side effects are bothersome, your healthcare provider can offer medical advice on how to deal with your symptoms